Agilent Technologies to Acquire Biocare Medical for $950 Million

GHO Capital and Excellere Partners Invest in Biocare Medical

December 9, 2021

Medical Devices

London-based GHO Capital has invested in Biocare Medical, a California-headquartered developer of immunohistochemistry reagents and diagnostic instrumentation, alongside existing investor Excellere Partners. The capital will be used to accelerate R&D, expand the instrument offering, and support international expansion to capture growing demand for oncology diagnostics.

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.

Agilent Technologies Acquires Avida Biomed

January 4, 2023

Biotechnology

Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.

Merck Acquires Imago BioSciences for $1.35 Billion

November 21, 2022

Biotechnology

Merck (MSD) entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Imago BioSciences in an all-cash deal valued at approximately $1.35 billion (=$36.00 per share). Merck will commence a tender offer for all outstanding shares, with the transaction expected to close in the first quarter of 2023, subject to customary conditions.

PerkinElmer Acquires BioLegend for Approximately $5.25 Billion

July 26, 2021

Biotechnology

PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.